WO2007054976A3 - Lipid based controlled release pharmaceutical composition - Google Patents

Lipid based controlled release pharmaceutical composition Download PDF

Info

Publication number
WO2007054976A3
WO2007054976A3 PCT/IN2006/000438 IN2006000438W WO2007054976A3 WO 2007054976 A3 WO2007054976 A3 WO 2007054976A3 IN 2006000438 W IN2006000438 W IN 2006000438W WO 2007054976 A3 WO2007054976 A3 WO 2007054976A3
Authority
WO
WIPO (PCT)
Prior art keywords
controlled release
release pharmaceutical
pharmaceutical composition
lipid based
based controlled
Prior art date
Application number
PCT/IN2006/000438
Other languages
French (fr)
Other versions
WO2007054976A2 (en
Inventor
Rajesh Jain
Kour Chand Jindal
Sampath Kumar Devarajan
Original Assignee
Panacea Biotec Ltd
Rajesh Jain
Kour Chand Jindal
Sampath Kumar Devarajan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Biotec Ltd, Rajesh Jain, Kour Chand Jindal, Sampath Kumar Devarajan filed Critical Panacea Biotec Ltd
Publication of WO2007054976A2 publication Critical patent/WO2007054976A2/en
Publication of WO2007054976A3 publication Critical patent/WO2007054976A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Abstract

Novel controlled release pharmaceutical compositions are provided which release the active agent(s) over an extended period of time comprising a core wherein the said core comprises at least one active agent(s) which is preferably water soluble, a lipid system comprising at least one lipid component(s), at least one water insoluble release modifier(s), at least one channel forming agent(s) and optionally one or more pharmaceutically acceptable excipients; and at least one coat. Preferably the coating composition comprises at least one hydrophilic pH independent polymer(s) and optionally one or more pharmaceutically acceptable excipients. Also provided is a process of preparation of such compositions and method of using them.
PCT/IN2006/000438 2005-11-08 2006-11-07 Lipid based controlled release pharmaceutical composition WO2007054976A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2985DE2005 2005-11-08
IN2985DEL/2005 2005-11-08

Publications (2)

Publication Number Publication Date
WO2007054976A2 WO2007054976A2 (en) 2007-05-18
WO2007054976A3 true WO2007054976A3 (en) 2007-08-09

Family

ID=38023688

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2006/000438 WO2007054976A2 (en) 2005-11-08 2006-11-07 Lipid based controlled release pharmaceutical composition

Country Status (1)

Country Link
WO (1) WO2007054976A2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8377977B2 (en) 2004-08-13 2013-02-19 Boehringer Ingelheim International Gmbh Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
US8637540B2 (en) 2003-11-26 2014-01-28 Acura Pharmaceuticals Compositions for deterring abuse of opioid containing dosage forms
US8715728B2 (en) 2004-08-13 2014-05-06 Boehringer Ingelheim International Gmbh Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
US8901113B2 (en) 2009-09-30 2014-12-02 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
US9101636B2 (en) 2012-11-30 2015-08-11 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
WO2007090882A2 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Pharmaceutical extended release compositions comprising pramipexole
US20100143471A1 (en) * 2007-03-21 2010-06-10 Lupin Limited Novel reduced dose pharmaceutical compositions of fexofenadine and pseudoephedrine
CA2684550A1 (en) * 2007-04-24 2008-10-30 Boehringer Ingelheim International Gmbh Combination with an extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
WO2010083360A2 (en) * 2009-01-16 2010-07-22 Mutual Pharmaceutical Company, Inc. Controlled-release formulations
US20100297195A1 (en) * 2009-05-20 2010-11-25 Ranbaxy Laboratories Limited Controlled release lamotrigine formulations
TR200905670A1 (en) * 2009-07-22 2011-02-21 Sanovel �La� San.Ve T�C.A.�. Levetiracetam pharmaceutical compositions for prolonged release
TR201001862A1 (en) * 2010-03-11 2011-10-21 Sanovel �La� San.Ve T�C.A.�. Controlled release pramipexole formulations.
EP2380560A1 (en) * 2010-04-22 2011-10-26 ratiopharm GmbH Matrix tablets containing pramipexol
KR101307334B1 (en) * 2010-07-02 2013-09-12 주식회사 바이오파마티스 Sustained-release pharmaceutical composition comprising pramipexole or pharmaceutically acceptable salt thereof having improved stability
WO2013058409A1 (en) 2011-10-21 2013-04-25 Takeda Pharmaceutical Company Limited Sustained-release preparation
CN104367562A (en) * 2013-08-15 2015-02-25 上海星泰医药科技有限公司 Pramipexole dihydrochloride slow-release tablets and preparation method thereof
US20190000126A1 (en) * 2015-01-07 2019-01-03 Corr-Jensen Inc. Compositions and methods for enhancing athletic performance
US11103581B2 (en) 2015-08-31 2021-08-31 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
CN109982690A (en) * 2016-05-11 2019-07-05 雷尔玛达治疗公司 Wear-resisting opioid formulation
CN106727357B (en) * 2017-01-19 2020-09-18 杭州益品新五丰药业有限公司 Acyclovir granules and preparation method thereof
CN109125270B (en) * 2017-06-27 2021-03-19 广州帝奇医药技术有限公司 Solid preparation and preparation method thereof
WO2021033180A1 (en) * 2019-08-16 2021-02-25 Adel Penhasi Adhesive drug delivery microparticles and a product comprising thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003063834A1 (en) * 2002-02-01 2003-08-07 Pacific Corporation Multi-stage oral drug controlled-release system
WO2004012699A2 (en) * 2002-08-05 2004-02-12 Torrent Pharmaceuticals Limited Modified release composition comprising coated micro matrix particles containing the high soluble active ingredient and a release controlling agent
US20040062800A1 (en) * 2000-12-20 2004-04-01 Burnside Beth A. Sustained release pharmaceutical dosage forms with minimized ph dependent dissolution profiles

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040062800A1 (en) * 2000-12-20 2004-04-01 Burnside Beth A. Sustained release pharmaceutical dosage forms with minimized ph dependent dissolution profiles
WO2003063834A1 (en) * 2002-02-01 2003-08-07 Pacific Corporation Multi-stage oral drug controlled-release system
WO2004012699A2 (en) * 2002-08-05 2004-02-12 Torrent Pharmaceuticals Limited Modified release composition comprising coated micro matrix particles containing the high soluble active ingredient and a release controlling agent

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8637540B2 (en) 2003-11-26 2014-01-28 Acura Pharmaceuticals Compositions for deterring abuse of opioid containing dosage forms
US8822489B2 (en) 2003-11-26 2014-09-02 Acura Pharmaceuticals Abuse deterrent compositions and methods of making same
US9492443B2 (en) 2003-11-26 2016-11-15 Acura Pharmaceuticals, Inc. Abuse deterrent compositions and methods of making same
US8377977B2 (en) 2004-08-13 2013-02-19 Boehringer Ingelheim International Gmbh Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
US8715728B2 (en) 2004-08-13 2014-05-06 Boehringer Ingelheim International Gmbh Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
US8901113B2 (en) 2009-09-30 2014-12-02 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
US9101636B2 (en) 2012-11-30 2015-08-11 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
US9320796B2 (en) 2012-11-30 2016-04-26 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient

Also Published As

Publication number Publication date
WO2007054976A2 (en) 2007-05-18

Similar Documents

Publication Publication Date Title
WO2007054976A3 (en) Lipid based controlled release pharmaceutical composition
WO2008022932A3 (en) Controlled release system and method for manufacturing the same
WO2007000778A3 (en) Modified release pharmaceutical compositions on the basis of two polymers and processes thereof
TNSN08365A1 (en) Sustained release pharmaceutical composition on the basis of release system comprising an acid-soluble polymer and a ph-dependent polymer
WO2006039499A3 (en) Method for improving the biovailability of orally delivered therapeutics
WO2007020259A3 (en) Controlled release pharmaceutical compositions for acid labile drugs
WO2008061226A3 (en) Sustained-release formulations of topiramate
WO2006121941A3 (en) Pharmaceutical compositions comprising imatinib and a release retardant
WO2005123134A3 (en) A controlled release delivery system for metformin
WO2001052816A3 (en) Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same
BR9915087A (en) Enteric coated oral pharmaceutical formulation, use of a hydroxypropyl cellulose (hpc) quality, process for the manufacture of an enteric coated oral pharmaceutical formulation, use of a pharmaceutical formulation, and method for the treatment of gastrointestinal diseases in mammals, including man
WO2007086078A3 (en) Novel pharmaceutical compositions and process of preparation thereof
WO2007034503A3 (en) Controlled release dosage formulation of duloxetine
WO2005069933A3 (en) Methods of treating an inflammatory-related disease
EP2110135A3 (en) A pharmaceutical composition for treating depression and method for preparation thereof
WO2006058250A3 (en) Orally disintegrating compositions
WO2010037854A3 (en) Alcohol-resistant sustained-release oral pharmaceutical form based on microgranules
WO2005079861A3 (en) Polymeric water soluble prodrugs
WO2001070197A3 (en) Method for preparing high pressure/high shear dispersions containing physiologically active ingredients
WO2008084698A1 (en) Tacrolimus sustained release pharmaceutical composition
WO2003057150A3 (en) A stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof
MX341015B (en) Extended-release dosage form.
WO2004066984A3 (en) Improved taste masking pharmaceutical composition and process for its preparation
WO2003041656A3 (en) Soluble drug extended release system
WO2008023390A3 (en) Modified release pharmaceutical composition of bupropion hydrochloride

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06821697

Country of ref document: EP

Kind code of ref document: A2

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)